Germany Dermatology Drugs Market Analysis Report 2022 to 2030

Germany Dermatology Drugs Market Analysis

$ 3999

By 2030, it is anticipated that the Germany dermatology drugs market will reach a value of $1,240 Mn from $622 Mn in 2022, growing at a CAGR of 9% during 2022-2030. The market is primarily dominated by local players such as Merck KGaA, Stada Arzneimittel, and Beiersdorf. The market is driven by innovation and development, better health insurance, and strict regulations. The dermatology drug market in Germany is segmented by drug class, drug type, prescription mode, indication, route of administration, end user and distribution channel.

ID: IN10DEPH008 CATEGORY: Pharmaceuticals GEOGRAPHY: Germany AUTHOR: Dr. Vishwa Modhia

Buy Now

Germany Dermatology Drugs Market Analysis Summary

By 2030, it is anticipated that the Germany dermatology drugs market will reach a value of $1,240 Mn from $622 Mn in 2022, growing at a CAGR of 9% during 2022-30.

Dermatological diseases are among the most frequent reasons for seeking medical care in Germany. About 25% of the German working population requires treatment at least once a year due to dermatological findings.

In 2019, the health expenditure in Germany was $5440 per capita, which is 11.7% of their GDP. The out-of-pocket expenditure of the people of Germany has decreased from 15% in 2007 to 12% in 2019. Also, Germany ranks fourth on the global ranking in healthcare expenditure, which is $4,226 Bn. The country also has a social health insurance system that is the oldest in the world.

germany dermatology drugs market analysis

Market Dynamics

Market Growth Drivers Analysis

Treatment for various dermatological conditions like psoriasis and eczema has been using biologic drugs, which are made from living organisms or their derivatives, which can be a potential growth area. In Germany, there has been an increase in the use of cosmeceuticals, which are cosmetics with medicinal properties. These products are used to treat a number of skin conditions, including hyperpigmentation, acne, and aging. Modern drug therapies, which will also spur the market, have the potential to replace inpatient care in the non-surgical dermatology field.

Market Restraints

In Germany, out-of-pocket costs have decreased overall, but they are still 20% for pharmaceuticals. Unsurely of medical coverage of the dermatology drugs hamper the market growth in Germany.

Competitive Landscape

Key Players

Beiersdorf (DEU)
Stada Arzneimittel (DEU)
Bayer (DEU)
Merck KGaA (DEU)
Boehringer Ingelheim (DEU)
Stiefel (DEU)
Galderma
Novartis
GlaxoSmithKline
Pfizer
Sanofi

Healthcare Policies and Regulatory Landscape

In Germany, a number of authorities are in charge of monitoring drug use because of the federal structure. Low-molecular and biotechnologically produced drugs and medical devices must be approved by and under the supervision of the Bonn-based Federal Institute for Drugs and Medical Devices (BfArM).

Reimbursement Scenario

The statutory health insurance in Germany must receive a general mandatory markdown payment from all pharmaceutical companies. This payment is sometimes referred to as the "mandatory discount." This general mandatory discount, which is currently set at 7% of the company's sales price, is applicable to all medications. This required discount will rise from 5% to 12% under the new GKV-FinStG in 2023.

1. Executive Summary
1.1 Disease Overview
1.2 Global Scenario
1.3 Country Overview
1.4 Healthcare Scenario in Country
1.5 Patient Journey
1.6 Health Insurance Coverage in Country
1.7 Active Pharmaceutical Ingredient (API)
1.8 Recent Developments in the Country

2. Market Size and Forecasting
2.1 Epidemiology of Disease
2.2 Market Size (With Excel & Methodology)
2.3 Market Segmentation (Check all Segments in Segmentation Section)

3. Market Dynamics
3.1 Market Drivers
3.2 Market Restraints

4. Competitive Landscape
4.1 Major Market Share

4.2 Key Company Profile (Check all Companies in the Summary Section)

4.2.1 Company
4.2.1.1 Overview
4.2.1.2 Product Applications and Services
4.2.1.3 Recent Developments
4.2.1.4 Partnerships Ecosystem
4.2.1.5 Financials (Based on Availability)

5. Reimbursement Scenario
5.1 Reimbursement Regulation
5.2 Reimbursement Process for Diagnosis
5.3 Reimbursement Process for Treatment

6. Methodology and Scope

Dermatology Drugs Market Segmentation

The Dermatology Drugs Market is segmented as mentioned below

By Disease (Revenue, USD Billion):

Psoriasis
Acne Vulgaris
Atopic Dermatitis
Eczema
Rosacea
Itchthyosis
Vitiligo
Others

By Route Of Administration (Revenue, USD Billion):

Oral
Parenteral
Topical

By Distribution Channel (Revenue, USD Billion):

Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
Others

Methodology for Database Creation

Our database offers a comprehensive list of healthcare centers, meticulously curated to provide detailed information on a wide range of specialties and services. It includes top-tier hospitals, clinics, and diagnostic facilities across 30 countries and 24 specialties, ensuring users can find the healthcare services they need.

Additionally, we provide a comprehensive list of Key Opinion Leaders (KOLs) based on your requirements. Our curated list captures various crucial aspects of the KOLs, offering more than just general information. Whether you're looking to boost brand awareness, drive engagement, or launch a new product, our extensive list of KOLs ensures you have the right experts by your side. Covering 30 countries and 36 specialties, our database guarantees access to the best KOLs in the healthcare industry, supporting strategic decisions and enhancing your initiatives.

How Do We Get It?

Our database is created and maintained through a combination of secondary and primary research methodologies.

1. Secondary Research

With many years of experience in the healthcare field, we have our own rich proprietary data from various past projects. This historical data serves as the foundation for our database. Our continuous process of gathering data involves:

Analyzing historical proprietary data collected from multiple projects.
Regularly updating our existing data sets with new findings and trends.
Ensuring data consistency and accuracy through rigorous validation processes.

With extensive experience in the field, we have developed a proprietary GenAI-based technology that is uniquely tailored to our organization. This advanced technology enables us to scan a wide array of relevant information sources across the internet. Our data-gathering process includes:

Searching through academic conferences, published research, citations, and social media platforms
Collecting and compiling diverse data to build a comprehensive and detailed database
Continuously updating our database with new information to ensure its relevance and accuracy

2. Primary Research

To complement and validate our secondary data, we engage in primary research through local tie-ups and partnerships. This process involves:

Collaborating with local healthcare providers, hospitals, and clinics to gather real-time data.
Conducting surveys, interviews, and field studies to collect fresh data directly from the source.
Continuously refreshing our database to ensure that the information remains current and reliable.
Validating secondary data through cross-referencing with primary data to ensure accuracy and relevance.

Combining Secondary and Primary Research

By integrating both secondary and primary research methodologies, we ensure that our database is comprehensive, accurate, and up-to-date. The combined process involves:

Merging historical data from secondary research with real-time data from primary research.
Conducting thorough data validation and cleansing to remove inconsistencies and errors.
Organizing data into a structured format that is easily accessible and usable for various applications.
Continuously monitoring and updating the database to reflect the latest developments and trends in the healthcare field.

Through this meticulous process, we create a final database tailored to each region and domain within the healthcare industry. This approach ensures that our clients receive reliable and relevant data, empowering them to make informed decisions and drive innovation in their respective fields.